Real-time disaster intelligence, alerts, and response tools.
Sunday, April 26, 2026
[ad_1] SHANGHAI, Dec. 8, 2024 /PRNewswire/ — December 8, 2024, Abbisko Therapeutics (HKEX: 02256) announced the presentation of preliminary Phase 2 study results for pimicotinib (ABSK021) in patients with chronic Graft-versus-Host Disease (cGvHD) who have […]
[ad_1] – The MANEUVER study met the primary endpoint with an objective response rate (ORR) at week 25 of 54.0% compared with 3.2% for placebo (p< 0.0001 ) –– Statistically significant and clinically meaningful improvements […]
[ad_1] SHANGHAI, Sept. 18, 2024 /PRNewswire/ — Abbisko Therapeutics (HKEX: 02256) is excited to announce the receipt of the ESMO 2024 Best Poster Award on September 16, 2024. The award was received for the presentation […]
